Vitamin D Level in Recurrent PV

Recurrent Pityriasis Versicolor Clinical Trial

Official title:

Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05067699
• Other study ID #: VitD&PV
• Status: Recruiting
• Start date: September 1, 2021
• Est. completion date: March 1, 2022

Study information

• Verified date: September 2021
• Source: Kasr El Aini Hospital
• Contact: Rana Hilal, M.D
• Phone: +201001488869
• Email: rana.hilal[@]kasralainy.edu.eg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: March 1, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
• Patients of both genders.
• Age =18 years old.

Exclusion Criteria:

• - Patients with other cutaneous diseases.
• Patient's having dandruff (scaly scalp) even if not symptomatizing.
• Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
• Patients with autoimmune diseases.
• Patients with immunodeficiency diseases.
• Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Related Conditions & MeSH terms

• Recurrent Pityriasis Versicolor
• Tinea Versicolor

Intervention

Diagnostic Test:
• Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D(25-OH-D).

Locations

Country	Name	City	State
Egypt	Kasr Al Ainy Teaching Hospital	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Kasr El Aini Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum 25(OH) D3 level	The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D(25-OH-D).	6months-1 year